Mydecine Innovations Group Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was CAD 7.65 million compared to CAD 5.64 million a year ago. Basic loss per share from continuing operations was CAD 0.41 compared to CAD 1.2 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0128 USD | -33.26% | +1.59% | -14.09% |
May. 01 | Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding | CI |
Feb. 23 | Mydecine Innovations Closes Partial Debt Settlement | MT |
1st Jan change | Capi. | |
---|---|---|
-14.09% | 788K | |
+32.34% | 49.46B | |
+2.28% | 42.58B | |
+49.11% | 42.49B | |
-5.26% | 29.09B | |
+12.42% | 26.61B | |
-23.40% | 18.64B | |
+8.47% | 13.16B | |
+30.52% | 12.55B | |
+24.00% | 12.1B |
- Stock Market
- Equities
- MYCOF Stock
- News Mydecine Innovations Group Inc.
- Mydecine Innovations Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023